Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 11,031,000, a decrease of 48.4% compared to RMB 21,387,000 in 2024[3] - Net loss before tax for the year was RMB 150,355,000, representing a 10.6% improvement from a loss of RMB 168,235,000 in 2024[3] - Financing costs increased significantly by 759.4% to RMB 6,583,000 from RMB 766,000 in 2024[3] - The company reported a net loss attributable to shareholders of RMB 150,355,000 for the year ended December 31, 2025, compared to a net loss of RMB 168,235,000 in 2024, representing a 10.6% improvement[22] - The company’s other income decreased by approximately 48.4% from RMB 21.4 million in 2024 to RMB 11.0 million in 2025, primarily due to reduced government subsidies and bank interest income[60] - The net other income and losses decreased from a gain of approximately RMB 11.8 million in 2024 to a loss of approximately RMB 4.2 million in 2025, mainly due to reduced fair value gains on financial assets and increased impairment losses[62] Research and Development - The company submitted the Biologics License Application (BLA) for its core product LZ901 to the National Medical Products Administration in January 2025, which was accepted in February 2025[4] - LZ901 demonstrated superior cellular immunogenicity and safety compared to the HZ/su vaccine in a head-to-head comparative study conducted in adults aged 50 and above[4] - The company completed Phase I clinical trials for LZ901 in the United States in September 2025, showing good safety and immunogenicity results[4] - The company’s recombinant RSV vaccine has entered the pre-IND application stage as of Q4 2025[5] - The product pipeline includes three clinical-stage candidates, including the core product LZ901, and six preclinical-stage candidates as of December 31, 2025[45] - The innovative Fabite® platform enhances the development of bispecific antibodies, providing a competitive edge in treating relapsed/refractory hematological malignancies[46] - The next-generation vaccine development focuses on improving immunogenicity and safety while enhancing patient experience through innovative antigen delivery techniques[46] - The company holds seven R&D patents related to its core product across multiple countries, indicating a strong intellectual property position in key markets[45] Assets and Liabilities - Total assets as of December 31, 2025, were RMB 921,126,000, a decrease from RMB 951,606,000 in 2024[7] - The company’s net asset value decreased to RMB 660,119,000 from RMB 853,591,000 in the previous year[7] - The company’s non-current assets (excluding financial instruments) as of December 31, 2025, amounted to RMB 599,696,000, an increase from RMB 577,236,000 as of December 31, 2024[13] - The total receivables, prepayments, and other receivables as of December 31, 2025, is RMB 17,989,000, down from RMB 25,627,000 as of December 31, 2024, showing a decrease of approximately 29.8%[28] - Bank borrowings increased significantly to RMB 259,614,000 in 2025 from RMB 54,914,000 in 2024, representing an increase of approximately 371.5%[38] - The company has a new bank loan agreement for RMB 200,000,000 for the construction of a research and commercial production base in Beijing, maturing five years from the first drawdown[38] Employee and Operational Expenses - The company’s employee benefit expenses totaled RMB 40,841,000 for the year ended December 31, 2025, down from RMB 68,181,000 in 2024, indicating cost control measures[20] - The group's administrative expenses decreased by approximately 20.1% from RMB 648 million in 2024 to about RMB 518 million in 2025[64] - Research and development expenses fell by approximately 28.6% from RMB 1,351 million in 2024 to about RMB 965 million in 2025, primarily due to reduced clinical expenses for LZ901[65] - Other expenses rose by approximately 108.6% from RMB 7 million in 2024 to about RMB 16 million in 2025, mainly due to increased costs of immune testing kits[67] Shareholder and Corporate Governance - The company did not declare or pay any dividends for the year ended December 31, 2025, consistent with the previous year[21] - The board does not recommend the payment of a final dividend for the year ending December 31, 2025[101] - The company has committed to high standards of corporate governance to protect shareholder interests and has complied with all applicable governance codes[93] - The company plans to utilize the repurchased H-shares for the 2025 share incentive plan[98] Future Plans and Developments - The company plans to accelerate the clinical development of its core product LZ901 and other preclinical products, including recombinant vaccines and bispecific antibodies[58] - The company aims to expand its product pipeline through independent development and collaborations[58] - The company has set aside HKD 38.8 million for the construction of a commercial production facility in Zhuhai, expected to be completed by the end of 2026[84] - The company plans to fully utilize the net proceeds from the global offering by the end of 2027[86]
绿竹生物(02480) - 2025 - 年度业绩